{"hands_on_practices": [{"introduction": "A cornerstone of pharmacology and toxicology is the unbound concentration hypothesis, which posits that only the free, unbound fraction of a drug is available to interact with biological targets. This practice [@problem_id:5049610] challenges you to apply this principle in a core safety assessment scenario. You will calculate the clinically relevant unbound drug exposure and compare it to the unbound concentration that causes an effect in an *in vitro* assay, thereby determining a realistic safety margin for hERG channel blockade.", "problem": "In the context of International Council for Harmonisation (ICH) Safety Pharmacology Guideline S7A core battery evaluations, translational decision-making commonly compares an in vitro unbound effect threshold to an in vivo unbound clinical exposure. Consider a small-molecule candidate with human plasma protein binding characterized by an unbound fraction $f_u$ and a maximum plasma concentration $C_{\\max}$ at steady state. The cardiovascular core battery includes a human Ether-Ã -go-go-Related Gene (hERG) assay performed in a buffered medium where nonspecific binding occurs, so only a fraction $f_{u,\\text{assay}}$ of the spiked total concentration is free. The unbound concentration at the hERG effect threshold is therefore the fraction of the total assay concentration that is free.\n\nUse the following scientifically plausible parameters:\n- Human plasma unbound fraction $f_u = 0.10$.\n- Human total maximum plasma concentration $C_{\\max} = 3\\,\\mathrm{\\mu M}$.\n- hERG total concentration producing $10\\%$ current inhibition in the assay, $IC_{10,\\text{total}} = 1.5\\,\\mathrm{\\mu M}$.\n- Assay unbound fraction $f_{u,\\text{assay}} = 0.50$.\n\nStarting only from core definitions that (i) the unbound fraction in plasma satisfies $f_u = \\frac{C_u}{C_{\\text{total}}}$, and (ii) the assay unbound fraction satisfies $f_{u,\\text{assay}} = \\frac{C_{u,\\text{assay}}}{C_{\\text{total,assay}}}$, derive the expressions for the unbound clinical exposure $C_{\\max,u}$ and the unbound in vitro threshold $IC_{10,u}$. Define the safety margin $M$ for the hERG core battery endpoint as the ratio of the unbound in vitro threshold to the unbound clinical exposure, and compute its value.\n\nReport the final answer as the dimensionless ratio $M$, rounded to four significant figures. If you display intermediate concentrations, express them in $\\mathrm{\\mu M}$. Briefly explain, in words, how inter-individual variability in $f_u$ (for example spanning $0.05$ to $0.20$) would be expected to alter $M$ and the interpretation of cardiac risk margins, but do not include this qualitative interpretation in your final numeric answer.", "solution": "The objective is to calculate the safety margin, $M$, defined as the ratio of the unbound in vitro effect threshold, $IC_{10,u}$, to the unbound clinical exposure, $C_{\\max,u}$.\n$$M = \\frac{IC_{10,u}}{C_{\\max,u}}$$\n\nFirst, we derive the expression for the unbound clinical exposure at maximum concentration, $C_{\\max,u}$. The problem provides the fundamental definition for unbound fraction in plasma:\n$$f_u = \\frac{C_u}{C_{\\text{total}}}$$\nwhere $C_u$ is the unbound plasma concentration and $C_{\\text{total}}$ is the total plasma concentration. To find the maximum unbound concentration, we apply this relationship at the maximum total plasma concentration, $C_{\\max}$. Thus, $C_u$ becomes $C_{\\max,u}$ and $C_{\\text{total}}$ becomes $C_{\\max}$.\n$$f_u = \\frac{C_{\\max,u}}{C_{\\max}}$$\nRearranging this expression to solve for $C_{\\max,u}$ gives:\n$$C_{\\max,u} = f_u \\times C_{\\max}$$\nSubstituting the given values, $f_u = 0.10$ and $C_{\\max} = 3\\,\\mathrm{\\mu M}$:\n$$C_{\\max,u} = 0.10 \\times 3\\,\\mathrm{\\mu M} = 0.3\\,\\mathrm{\\mu M}$$\n\nSecond, we derive the expression for the unbound in vitro effect threshold, $IC_{10,u}$. The problem provides a similar definition for the unbound fraction in the assay medium:\n$$f_{u,\\text{assay}} = \\frac{C_{u,\\text{assay}}}{C_{\\text{total,assay}}}$$\nHere, $C_{u,\\text{assay}}$ is the unbound concentration in the assay, and $C_{\\text{total,assay}}$ is the total (spiked) drug concentration. The unbound effect threshold, $IC_{10,u}$, corresponds to the unbound concentration when the total concentration is $IC_{10,\\text{total}}$. Therefore, we set $C_{u,\\text{assay}} = IC_{10,u}$ and $C_{\\text{total,assay}} = IC_{10,\\text{total}}$.\n$$f_{u,\\text{assay}} = \\frac{IC_{10,u}}{IC_{10,\\text{total}}}$$\nRearranging to solve for $IC_{10,u}$:\n$$IC_{10,u} = f_{u,\\text{assay}} \\times IC_{10,\\text{total}}$$\nSubstituting the given values, $f_{u,\\text{assay}} = 0.50$ and $IC_{10,\\text{total}} = 1.5\\,\\mathrm{\\mu M}$:\n$$IC_{10,u} = 0.50 \\times 1.5\\,\\mathrm{\\mu M} = 0.75\\,\\mathrm{\\mu M}$$\n\nFinally, we compute the safety margin $M$ by substituting the calculated unbound concentrations into its definition:\n$$M = \\frac{IC_{10,u}}{C_{\\max,u}} = \\frac{0.75\\,\\mathrm{\\mu M}}{0.3\\,\\mathrm{\\mu M}}$$\nThe units of concentration cancel out, yielding a dimensionless ratio:\n$$M = 2.5$$\nThe problem requires the answer to be rounded to four significant figures. Therefore, $M = 2.500$.\n\nRegarding inter-individual variability in the human plasma unbound fraction, $f_u$, the safety margin $M$ is defined as $M = \\frac{IC_{10,u}}{C_{\\max,u}} = \\frac{IC_{10,u}}{f_u \\times C_{\\max}}$. This expression shows that $M$ is inversely proportional to $f_u$. If $f_u$ varies among individuals, so will their unbound drug exposure and their hERG safety margin. For an individual with lower plasma protein binding (a higher $f_u$, e.g., $f_u = 0.20$), the unbound exposure $C_{\\max,u}$ would increase, leading to a smaller safety margin $M$. Conversely, an individual with higher plasma protein binding (a lower $f_u$, e.g., $f_u = 0.05$) would have a lower $C_{\\max,u}$ and a larger safety margin. This variability is a critical consideration in translational risk assessment, as individuals at the higher end of the $f_u$ range are at a greater potential risk for concentration-dependent adverse effects such as Torsades de Pointes arrhythmia, which is associated with hERG channel blockade.", "answer": "$$\\boxed{2.500}$$", "id": "5049610"}, {"introduction": "While hERG channel inhibition is a primary concern, a drug's overall cardiovascular risk profile is determined by its integrated effects on multiple ion channels. This exercise [@problem_id:5049668] moves beyond a single-target assessment to a more holistic view of cardiac safety. By calculating the fractional block for several key currents and constructing a net risk index, you will practice evaluating the critical balance between pro-arrhythmic and potentially mitigating channel interactions, reflecting modern approaches to cardiac safety assessment.", "problem": "A small-molecule candidate intended for chronic oral therapy is evaluated in the International Council for Harmonisation (ICH) Safety Pharmacology core battery for cardiovascular ion channel effects. Concentration-response studies in heterologous expression systems yield half maximal inhibitory concentrations ($IC_{50}$) for four key channels: the human Ether-Ã -go-go-Related Gene (hERG) channel mediating the rapid delayed rectifier potassium current ($I_{Kr}$), the slow delayed rectifier potassium current ($I_{Ks}$), the voltage-gated cardiac sodium channel ($\\mathrm{Nav}1.5$), and the L-type calcium channel ($\\mathrm{Cav}1.2$). The measured $IC_{50}$ values are $IC_{50,I_{Kr}}=0.03\\,\\mu\\mathrm{M}$, $IC_{50,I_{Ks}}=3.00\\,\\mu\\mathrm{M}$, $IC_{50,\\mathrm{Nav}1.5}=10.0\\,\\mu\\mathrm{M}$, and $IC_{50,\\mathrm{Cav}1.2}=25.0\\,\\mu\\mathrm{M}$. The projected maximum unbound plasma concentration at steady state is $C_{\\max,u}=0.15\\,\\mu\\mathrm{M}$.\n\nStarting from the one-to-one binding (Langmuir) model at equilibrium and the definition of $IC_{50}$ as the concentration that produces $50\\%$ inhibition under a Hill coefficient of $1$, derive the fractional block function $B(C)$ for a channel as a function of free concentration $C$ and its $IC_{50}$. Then, using $C=C_{\\max,u}$, compute the fractional block $B(C_{\\max,u})$ for each channel and construct a net repolarization-risk index defined as\n$$\nR \\equiv B_{I_{Kr}}(C_{\\max,u}) - B_{I_{Ks}}(C_{\\max,u}).\n$$\nAssume that fractional block is proportional to reduction in current amplitude and that $I_{Kr}$ block increases arrhythmic risk while $I_{Ks}$ block can mitigate it via repolarization reserve. Provide a brief interpretation of the balance between $I_{Kr}$ and $I_{Ks}$ blocks in terms of translational risk. Express the final numerical value of $R$ as an exact simplified fraction with no units. All concentrations are in $\\mu\\mathrm{M}$, and fractional blocks must be expressed as decimal fractions or rational numbers between $0$ and $1$.", "solution": "The first step is to derive the fractional block function, $B(C)$, for a channel as a function of the free drug concentration, $C$, and its half maximal inhibitory concentration, $IC_{50}$. The problem specifies a one-to-one binding (Langmuir) model at equilibrium with a Hill coefficient of $1$.\n\nLet $Ch$ represent the unbound channel, $C$ the free drug concentration, and $C \\cdot Ch$ the drug-bound (blocked) channel. The binding reaction at equilibrium is:\n$$\nC + Ch \\rightleftharpoons C \\cdot Ch\n$$\nThe dissociation constant, $K_d$, is defined as:\n$$\nK_d = \\frac{[C][Ch]}{[C \\cdot Ch]}\n$$\nThe total concentration of channels, $[Ch]_{\\text{total}}$, is the sum of unbound and bound channels:\n$$\n[Ch]_{\\text{total}} = [Ch] + [C \\cdot Ch]\n$$\nThe fractional block, $B(C)$, is the ratio of the concentration of blocked channels to the total concentration of channels:\n$$\nB(C) = \\frac{[C \\cdot Ch]}{[Ch]_{\\text{total}}} = \\frac{[C \\cdot Ch]}{[Ch] + [C \\cdot Ch]}\n$$\nFrom the definition of $K_d$, we can express the unbound channel concentration $[Ch]$ as $[Ch] = K_d \\frac{[C \\cdot Ch]}{[C]}$. Substituting this into the equation for $B(C)$:\n$$\nB(C) = \\frac{[C \\cdot Ch]}{K_d \\frac{[C \\cdot Ch]}{[C]} + [C \\cdot Ch]}\n$$\nDividing the numerator and denominator by $[C \\cdot Ch]$ yields:\n$$\nB(C) = \\frac{1}{\\frac{K_d}{C} + 1} = \\frac{C}{C + K_d}\n$$\nThis is the Hill-Langmuir equation for a system with a Hill coefficient of $1$. The problem defines $IC_{50}$ as the concentration at which $50\\%$ inhibition (block) occurs. Therefore, when $C = IC_{50}$, $B(IC_{50}) = 0.5$. Substituting this condition into the derived equation:\n$$\n0.5 = \\frac{IC_{50}}{IC_{50} + K_d}\n$$\nSolving for $K_d$:\n$$\n0.5 (IC_{50} + K_d) = IC_{50} \\implies 0.5 IC_{50} + 0.5 K_d = IC_{50} \\implies 0.5 K_d = 0.5 IC_{50} \\implies K_d = IC_{50}\n$$\nThus, for this model, the dissociation constant is equal to the half maximal inhibitory concentration. The fractional block function $B(C)$ can be written in terms of $IC_{50}$ as:\n$$\nB(C) = \\frac{C}{C + IC_{50}}\n$$\nNext, we compute the fractional block for each channel at the projected maximum unbound plasma concentration, $C_{\\max,u} = 0.15\\,\\mu\\mathrm{M}$.\n\nFor the $I_{Kr}$ channel (hERG):\n$IC_{50,I_{Kr}} = 0.03\\,\\mu\\mathrm{M}$\n$$\nB_{I_{Kr}}(C_{\\max,u}) = \\frac{C_{\\max,u}}{C_{\\max,u} + IC_{50,I_{Kr}}} = \\frac{0.15}{0.15 + 0.03} = \\frac{0.15}{0.18} = \\frac{15}{18} = \\frac{5}{6}\n$$\n\nFor the $I_{Ks}$ channel:\n$IC_{50,I_{Ks}} = 3.00\\,\\mu\\mathrm{M}$\n$$\nB_{I_{Ks}}(C_{\\max,u}) = \\frac{C_{\\max,u}}{C_{\\max,u} + IC_{50,I_{Ks}}} = \\frac{0.15}{0.15 + 3.00} = \\frac{0.15}{3.15} = \\frac{15}{315} = \\frac{1}{21}\n$$\n\nFor the $\\mathrm{Nav}1.5$ channel:\n$IC_{50,\\mathrm{Nav}1.5} = 10.0\\,\\mu\\mathrm{M}$\n$$\nB_{\\mathrm{Nav}1.5}(C_{\\max,u}) = \\frac{C_{\\max,u}}{C_{\\max,u} + IC_{50,\\mathrm{Nav}1.5}} = \\frac{0.15}{0.15 + 10.0} = \\frac{0.15}{10.15} = \\frac{15}{1015} = \\frac{3}{203}\n$$\n\nFor the $\\mathrm{Cav}1.2$ channel:\n$IC_{50,\\mathrm{Cav}1.2} = 25.0\\,\\mu\\mathrm{M}$\n$$\nB_{\\mathrm{Cav}1.2}(C_{\\max,u}) = \\frac{C_{\\max,u}}{C_{\\max,u} + IC_{50,\\mathrm{Cav}1.2}} = \\frac{0.15}{0.15 + 25.0} = \\frac{0.15}{25.15} = \\frac{15}{2515} = \\frac{3}{503}\n$$\n\nNow, we compute the net repolarization-risk index, $R$, defined as:\n$$\nR \\equiv B_{I_{Kr}}(C_{\\max,u}) - B_{I_{Ks}}(C_{\\max,u})\n$$\nSubstituting the calculated fractional block values for $I_{Kr}$ and $I_{Ks}$:\n$$\nR = \\frac{5}{6} - \\frac{1}{21}\n$$\nTo subtract the fractions, we find a common denominator, which is the least common multiple of $6$ and $21$. Since $6=2 \\times 3$ and $21=3 \\times 7$, the LCM is $2 \\times 3 \\times 7 = 42$.\n$$\nR = \\frac{5 \\times 7}{6 \\times 7} - \\frac{1 \\times 2}{21 \\times 2} = \\frac{35}{42} - \\frac{2}{42} = \\frac{35 - 2}{42} = \\frac{33}{42}\n$$\nSimplifying the fraction by dividing the numerator and denominator by their greatest common divisor, which is $3$:\n$$\nR = \\frac{11}{14}\n$$\n\nInterpretation of the balance:\nThe fractional block of the $I_{Kr}$ current at the maximal therapeutic concentration is $B_{I_{Kr}}(C_{\\max,u}) = \\frac{5}{6} \\approx 83.3\\%$. The block of the $I_{Ks}$ current is $B_{I_{Ks}}(C_{\\max,u}) = \\frac{1}{21} \\approx 4.8\\%$. $I_{Kr}$ is the primary rapid repolarizing current in the human ventricle, and its inhibition is strongly associated with delayed repolarization (QT prolongation) and increased risk of Torsades de Pointes (TdP) arrhythmia. $I_{Ks}$ provides a \"repolarization reserve,\" meaning that if $I_{Kr}$ is compromised, a robust $I_{Ks}$ can help maintain normal repolarization. However, this drug candidate exhibits potent block of $I_{Kr}$ and negligible block of $I_{Ks}$. The large positive value of the risk index, $R = \\frac{11}{14} \\approx 0.786$, quantifies this severe imbalance. The strong pro-arrhythmic effect of $I_{Kr}$ inhibition is not counteracted by any significant effect on $I_{Ks}$. From a translational safety perspective, this profile signals a high risk of life-threatening cardiac arrhythmia in humans, making the compound a poor candidate for further development, especially for chronic therapy.", "answer": "$$\\boxed{\\frac{11}{14}}$$", "id": "5049668"}, {"introduction": "The analysis of *in vivo* electrocardiogram (ECG) data is a critical component of the cardiovascular safety core battery, and a key challenge is to dissociate a drug's direct effect on ventricular repolarization from changes in heart rate. This hands-on practice [@problem_id:5049678] simulates this essential data analysis task. You will apply the standard Fridericia correction to a set of QT and RR interval data and then use summary statistics to assess whether a compound's effect is significant relative to the assay's sensitivity.", "problem": "You are tasked with implementing a program that operationalizes a core analytical step in preclinical safety pharmacology: correcting ventricular repolarization duration for heart rate using a power-law invariance assumption corresponding to the Fridericia-corrected QT interval (QTcF). Your task is to formalize the correction, compute summary statistics, and assess whether observed treatment effects surpass an assay sensitivity threshold. The analysis must be carried out on the provided test suite.\n\nFundamental base and principles:\n- The R-R interval (RR) is the cycle length between heartbeats, measured in seconds.\n- The uncorrected QT interval (QT) is the ventricular depolarization-repolarization duration measured in milliseconds.\n- Empirically, ventricular repolarization scales with cycle length approximately as a power law, that is, $QT \\propto RR^{b}$ with exponent $b = \\tfrac{1}{3}$ for the Fridericia method. A heart-rate invariant index $Q$ should satisfy invariance under uniform scaling of $RR$ when $QT$ varies as $RR^{b}$.\n\nRequired derivations and computations:\n1. Using the invariance principle and the empirical relationship $QT \\propto RR^{b}$ with $b = \\tfrac{1}{3}$, derive an expression for a heart-rate invariant repolarization index $Q$ expressed in milliseconds. This defines the Fridericia-corrected QT quantity to be used for all computations.\n2. For each treatment, compute this corrected value $Q$ for every beat and summarize the distribution per treatment by its mean and standard deviation, where the mean is\n   $$\\bar{x} = \\frac{1}{n} \\sum_{i=1}^{n} x_i,$$\n   and the sample standard deviation is\n   $$s = \\sqrt{\\frac{1}{n-1}\\sum_{i=1}^{n} (x_i - \\bar{x})^2}.$$\n   Express the mean and standard deviation in milliseconds, each rounded to one decimal place.\n3. Let the vehicle treatment be the reference with mean $\\bar{x}_{\\mathrm{veh}}$. For each non-vehicle treatment $d$ with mean $\\bar{x}_d$, compute the difference $\\Delta_d = \\bar{x}_d - \\bar{x}_{\\mathrm{veh}}$ in milliseconds. Using an assay sensitivity threshold $S = 7.0 \\,\\mathrm{ms}$, classify whether the observed mean difference exceeds assay sensitivity by evaluating the boolean condition\n   $$(\\bar{x}_d - \\bar{x}_{\\mathrm{veh}}) > S.$$\n   Report this as a boolean per non-vehicle treatment. Only positive differences are considered as exceeding the assay sensitivity.\n4. Units: All corrected values, means, differences, and standard deviations must be expressed in milliseconds. Round means and standard deviations to one decimal place.\n\nTest suite (these are the only inputs to use; you must hard-code them in your program):\n- Treatment \"Vehicle\": $RR$ in seconds, $QT$ in milliseconds:\n  - $($ $0.80$, $221.3$ $)$\n  - $($ $0.78$, $223.3$ $)$\n  - $($ $0.82$, $221.2$ $)$\n  - $($ $0.76$, $220.3$ $)$\n  - $($ $0.84$, $226.4$ $)$\n  - $($ $0.79$, $220.1$ $)$\n  - $($ $0.81$, $224.9$ $)$\n  - $($ $0.77$, $219.6$ $)$\n- Treatment \"LowDose\": $RR$ in seconds, $QT$ in milliseconds:\n  - $($ $0.70$, $220.35$ $)$\n  - $($ $0.72$, $219.6$ $)$\n  - $($ $0.74$, $224.56$ $)$\n  - $($ $0.68$, $214.83$ $)$\n  - $($ $0.75$, $223.99$ $)$\n  - $($ $0.73$, $221.52$ $)$\n  - $($ $0.69$, $215.39$ $)$\n  - $($ $0.71$, $220.90$ $)$\n- Treatment \"HighDose\": $RR$ in seconds, $QT$ in milliseconds:\n  - $($ $0.90$, $247.24$ $)$\n  - $($ $0.95$, $248.21$ $)$\n  - $($ $0.92$, $248.05$ $)$\n  - $($ $1.00$, $254.00$ $)$\n  - $($ $0.88$, $245.01$ $)$\n  - $($ $0.96$, $248.99$ $)$\n  - $($ $0.91$, $246.63$ $)$\n  - $($ $0.89$, $243.35$ $)$\n\nFinal output specification:\n- Your program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets, with no spaces.\n- The output must be a list of three elements in the following order:\n  1. For \"Vehicle\": a two-element list $[$ mean in milliseconds rounded to one decimal place, standard deviation in milliseconds rounded to one decimal place $]$.\n  2. For \"LowDose\": a three-element list $[$ mean in milliseconds rounded to one decimal place, standard deviation in milliseconds rounded to one decimal place, boolean indicating whether the mean difference strictly exceeds $S = 7.0 \\,\\mathrm{ms}$ relative to Vehicle $]$.\n  3. For \"HighDose\": a three-element list of the same structure as for \"LowDose\".\n- Example of the required output structural form (placeholders shown, not actual values): $[[m_{\\mathrm{veh}},s_{\\mathrm{veh}}],[m_{\\mathrm{low}},s_{\\mathrm{low}},B_{\\mathrm{low}}],[m_{\\mathrm{high}},s_{\\mathrm{high}},B_{\\mathrm{high}}]]$", "solution": "### Step 1: Derivation of the Heart-Rate Invariant Index ($Q$)\nThe problem mandates the derivation of a heart-rate invariant repolarization index, denoted as $Q$. The derivation is based on the principle that $Q$ must remain constant under a uniform scaling of the R-R interval ($RR$), given the empirical power-law relationship $QT \\propto RR^{b}$.\n\nLet the $RR$ interval be scaled by a factor $\\lambda > 0$, such that the new interval is $RR' = \\lambda \\cdot RR$.\nAccording to the power-law relationship, the QT interval scales accordingly:\n$$QT' \\propto (RR')^b = (\\lambda \\cdot RR)^b = \\lambda^b \\cdot RR^b$$\nSince $QT \\propto RR^b$, we can write $QT' = \\lambda^b \\cdot QT$.\n\nWe seek a function $Q(QT, RR)$ that is invariant under this transformation, meaning $Q(QT', RR') = Q(QT, RR)$. Let us test a functional form for $Q$ that is a product of powers of $QT$ and $RR$:\n$$Q(QT, RR) = QT^a \\cdot RR^k$$\nFor invariance, we must have:\n$$Q(QT', RR') = (QT')^a \\cdot (RR')^k = (\\lambda^b \\cdot QT)^a \\cdot (\\lambda \\cdot RR)^k = \\lambda^{ab} \\cdot QT^a \\cdot \\lambda^k \\cdot RR^k = \\lambda^{ab+k} \\cdot (QT^a \\cdot RR^k)$$\n$$Q(QT', RR') = \\lambda^{ab+k} \\cdot Q(QT, RR)$$\nFor $Q$ to be invariant, the exponent of the scaling factor $\\lambda$ must be zero:\n$$ab + k = 0$$\nThe simplest form of the index uses $QT$ linearly, so we set $a=1$. This gives:\n$$b + k = 0 \\implies k = -b$$\nThe problem specifies the Fridericia correction, for which the exponent is $b = \\frac{1}{3}$. Therefore, $k = -\\frac{1}{3}$.\nThe heart-rate invariant index $Q$ is thus given by:\n$$Q = \\frac{QT}{RR^{1/3}}$$\nThis quantity is known as the Fridericia-corrected QT interval (QTcF). The problem specifies that $QT$ is in milliseconds (ms) and $RR$ is in seconds (s). Conventionally, the numerical value of $RR$ in seconds is used in the formula, and the resulting index $Q$ is expressed in milliseconds (ms).\n\n### Step 2: Calculation and Statistical Analysis of Corrected QT (Q)\nFor each treatment group, we first compute the individual corrected QT values, $Q_i$, for each data pair $(RR_i, QT_i)$. Subsequently, we calculate the mean ($\\bar{x}$) and sample standard deviation ($s$) for the set of $Q_i$ values in each group.\n\nThe formulas for the mean and sample standard deviation for a set of $n$ values $\\{x_1, x_2, \\dots, x_n\\}$ are:\n$$\\bar{x} = \\frac{1}{n} \\sum_{i=1}^{n} x_i$$\n$$s = \\sqrt{\\frac{1}{n-1}\\sum_{i=1}^{n} (x_i - \\bar{x})^2}$$\n\nThe calculations for each treatment group are as follows, with $n=8$ for all groups.\n\n**Treatment: Vehicle**\nThe data are pairs of $(RR, QT)$. The calculated $Q_i = QT_i / RR_i^{1/3}$ values are:\n\\begin{itemize}\n    \\item $Q_1 = 221.3 / (0.80)^{1/3} \\approx 238.381$ ms\n    \\item $Q_2 = 223.3 / (0.78)^{1/3} \\approx 242.768$ ms\n    \\item $Q_3 = 221.2 / (0.82)^{1/3} \\approx 236.347$ ms\n    \\item $Q_4 = 220.3 / (0.76)^{1/3} \\approx 241.317$ ms\n    \\item $Q_5 = 226.4 / (0.84)^{1/3} \\approx 240.002$ ms\n    \\item $Q_6 = 220.1 / (0.79)^{1/3} \\approx 238.188$ ms\n    \\item $Q_7 = 224.9 / (0.81)^{1/3} \\approx 241.282$ ms\n    \\item $Q_8 = 219.6 / (0.77)^{1/3} \\approx 239.532$ ms\n\\end{itemize}\nMean: $\\bar{x}_{\\mathrm{veh}} \\approx 239.727$ ms\nSample Standard Deviation: $s_{\\mathrm{veh}} \\approx 2.066$ ms\nRounded to one decimal place: $\\bar{x}_{\\mathrm{veh}} \\approx 239.7$ ms, $s_{\\mathrm{veh}} \\approx 2.1$ ms.\n\n**Treatment: LowDose**\nThe calculated $Q_i$ values are:\n\\begin{itemize}\n    \\item $Q_1 = 220.35 / (0.70)^{1/3} \\approx 248.163$ ms\n    \\item $Q_2 = 219.60 / (0.72)^{1/3} \\approx 245.011$ ms\n    \\item $Q_3 = 224.56 / (0.74)^{1/3} \\approx 248.272$ ms\n    \\item $Q_4 = 214.83 / (0.68)^{1/3} \\approx 244.301$ ms\n    \\item $Q_5 = 223.99 / (0.75)^{1/3} \\approx 246.523$ ms\n    \\item $Q_6 = 221.52 / (0.73)^{1/3} \\approx 246.024$ ms\n    \\item $Q_7 = 215.39 / (0.69)^{1/3} \\approx 243.759$ ms\n    \\item $Q_8 = 220.90 / (0.71)^{1/3} \\approx 247.619$ ms\n\\end{itemize}\nMean: $\\bar{x}_{\\mathrm{low}} \\approx 246.209$ ms\nSample Standard Deviation: $s_{\\mathrm{low}} \\approx 1.749$ ms\nRounded to one decimal place: $\\bar{x}_{\\mathrm{low}} \\approx 246.2$ ms, $s_{\\mathrm{low}} \\approx 1.7$ ms.\n\n**Treatment: HighDose**\nThe calculated $Q_i$ values are:\n\\begin{itemize}\n    \\item $Q_1 = 247.24 / (0.90)^{1/3} \\approx 256.077$ ms\n    \\item $Q_2 = 248.21 / (0.95)^{1/3} \\approx 252.503$ ms\n    \\item $Q_3 = 248.05 / (0.92)^{1/3} \\approx 255.064$ ms\n    \\item $Q_4 = 254.00 / (1.00)^{1/3} = 254.000$ ms\n    \\item $Q_5 = 245.01 / (0.88)^{1/3} \\approx 255.666$ ms\n    \\item $Q_6 = 248.99 / (0.96)^{1/3} \\approx 252.394$ ms\n    \\item $Q_7 = 246.63 / (0.91)^{1/3} \\approx 254.520$ ms\n    \\item $Q_8 = 243.35 / (0.89)^{1/3} \\approx 252.993$ ms\n\\end{itemize}\nMean: $\\bar{x}_{\\mathrm{high}} \\approx 254.152$ ms\nSample Standard Deviation: $s_{\\mathrm{high}} \\approx 1.470$ ms\nRounded to one decimal place: $\\bar{x}_{\\mathrm{high}} \\approx 254.2$ ms, $s_{\\mathrm{high}} \\approx 1.5$ ms.\n\n\n### Step 3: Assessment of Treatment Effect\nWe compute the difference in mean corrected QT, $\\Delta_d = \\bar{x}_d - \\bar{x}_{\\mathrm{veh}}$, for each drug-treated group $d$ and compare it to the assay sensitivity threshold $S = 7.0$ ms. The condition to check is $\\Delta_d > S$.\n\n**LowDose vs. Vehicle:**\n$\\Delta_{\\mathrm{low}} = \\bar{x}_{\\mathrm{low}} - \\bar{x}_{\\mathrm{veh}} \\approx 246.209 - 239.727 = 6.482$ ms.\nThe condition is $6.482 > 7.0$, which is `False`.\n\n**HighDose vs. Vehicle:**\n$\\Delta_{\\mathrm{high}} = \\bar{x}_{\\mathrm{high}} - \\bar{x}_{\\mathrm{veh}} \\approx 254.152 - 239.727 = 14.425$ ms.\nThe condition is $14.425 > 7.0$, which is `True`.\n\n### Step 4: Final Output Assembly\nThe results are assembled into the specified list structure.\n\n1.  **Vehicle**: $[$mean, std$]$ = $[239.7, 2.1]$\n2.  **LowDose**: $[$mean, std, exceeds\\_S$]$ = $[246.2, 1.7, \\text{False}]$\n3.  **HighDose**: $[$mean, std, exceeds\\_S$]$ = $[254.2, 1.5, \\text{True}]$\n\nThe final output string is formed by concatenating these lists into a single list, ensuring no spaces are included in the final string representation, as per the problem specification.", "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\n\ndef solve():\n    \"\"\"\n    Solves the preclinical safety pharmacology problem by calculating Fridericia-corrected\n    QT intervals and performing statistical analysis.\n    \"\"\"\n    \n    # Hard-code the test suite data as specified.\n    # Format: { \"TreatmentName\": [(RR_sec, QT_msec), ...] }\n    test_suite = {\n        \"Vehicle\": [\n            (0.80, 221.3), (0.78, 223.3), (0.82, 221.2), (0.76, 220.3),\n            (0.84, 226.4), (0.79, 220.1), (0.81, 224.9), (0.77, 219.6)\n        ],\n        \"LowDose\": [\n            (0.70, 220.35), (0.72, 219.6), (0.74, 224.56), (0.68, 214.83),\n            (0.75, 223.99), (0.73, 221.52), (0.69, 215.39), (0.71, 220.90)\n        ],\n        \"HighDose\": [\n            (0.90, 247.24), (0.95, 248.21), (0.92, 248.05), (1.00, 254.00),\n            (0.88, 245.01), (0.96, 248.99), (0.91, 246.63), (0.89, 243.35)\n        ]\n    }\n    \n    # Assay sensitivity threshold in milliseconds.\n    S_threshold = 7.0\n    \n    # Store results for each treatment.\n    analysis_results = {}\n    \n    # Process each treatment group.\n    for treatment, data_points in test_suite.items():\n        # Step 1: Calculate the Fridericia-corrected QT (QTcF) for each beat.\n        # QTcF = QT / RR^(1/3)\n        rr_intervals = np.array([dp[0] for dp in data_points])\n        qt_intervals = np.array([dp[1] for dp in data_points])\n        \n        qtc_values = qt_intervals / np.power(rr_intervals, 1/3)\n        \n        # Step 2: Compute mean and sample standard deviation.\n        # The problem specifies sample standard deviation (ddof=1).\n        mean_qtc = np.mean(qtc_values)\n        std_qtc = np.std(qtc_values, ddof=1)\n        \n        analysis_results[treatment] = {\n            \"mean\": mean_qtc,\n            \"std\": std_qtc\n        }\n\n    # Step 3: Compute differences and assess against the threshold.\n    mean_veh = analysis_results[\"Vehicle\"][\"mean\"]\n    \n    # For LowDose\n    mean_low = analysis_results[\"LowDose\"][\"mean\"]\n    delta_low = mean_low - mean_veh\n    exceeds_S_low = delta_low > S_threshold\n    \n    # For HighDose\n    mean_high = analysis_results[\"HighDose\"][\"mean\"]\n    delta_high = mean_high - mean_veh\n    exceeds_S_high = delta_high > S_threshold\n\n    # Step 4: Format the results as specified.\n    # Round means and standard deviations to one decimal place.\n    veh_res = [\n        round(analysis_results[\"Vehicle\"][\"mean\"], 1),\n        round(analysis_results[\"Vehicle\"][\"std\"], 1)\n    ]\n    \n    low_res = [\n        round(mean_low, 1),\n        round(analysis_results[\"LowDose\"][\"std\"], 1),\n        exceeds_S_low\n    ]\n    \n    high_res = [\n        round(mean_high, 1),\n        round(analysis_results[\"HighDose\"][\"std\"], 1),\n        exceeds_S_high\n    ]\n\n    # Assemble the final list.\n    final_results = [veh_res, low_res, high_res]\n\n    # Generate the output string exactly as specified (no spaces).\n    inner_parts = []\n    for item in final_results:\n        # map(str, item) converts all elements (including bool) to strings.\n        # e.g., [246.2, 1.7, False] -> '246.2', '1.7', 'False'\n        inner_str = \",\".join(map(str, item))\n        inner_parts.append(f\"[{inner_str}]\")\n    \n    # Join the inner parts and enclose in the final brackets.\n    output_string = f\"[{','.join(inner_parts)}]\"\n\n    print(output_string)\n\nsolve()\n```", "id": "5049678"}]}